23andMe Investor Presentation Deck slide image

23andMe Investor Presentation Deck

Pharmaceutical Industry 7 years average time-to-IND¹ ~90% failure rate² NATURE GENETICS PUBLICATION 23andMe ~4 years to IND with CD96 drug Targets with genetic evidence have historically had a higher success rate³ The support of human genetic evidence for approved drug indications Nelson et. al 2015 ¹ IND = Investigational New Drug Application. fdareview.org, "The Drug Development and Approval Process" (2020). 2 Probability of success for a drug to be approved is estimated to be <12%. PhRMA, "Biopharmaceutical Research & Development: The Process Behind New Medicines" (2015). 3 Nature Genetics Publication, "The support of human genetic evidence for approved drug indications" (2015). Potential to More Efficiently Develop Novel Therapeutics by "Power, Need, and Speed" 28
View entire presentation